Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology.

Mayo Clinic 105

Mayo Clinic Dosage FDA Immunization 105

The Checkup by Singlecare

JUNE 5, 2025

Zepbound (tirzepatide) is a once-weekly injectable GIP/glucagon-like peptide-1 (GLP-1) receptor agonist that’s been approved by the Food and Drug Administration (FDA) to promote weight loss in adults with obesity or who are overweight with a weight-related health condition. You may need more or less than that based on your prescribed dosage.

Insurance 52

Insurance Customer Service Compounding Documentation 52

The Checkup by Singlecare

APRIL 24, 2025

It is approved by the Food and Drug Administration (FDA) for treating Type 2 diabetes. However, Mounjaro isnt listed on the 2025 Medicare Part D Formulary for Kaiser , so you may have to call your plan administrator for verification. Mounjaro is not generally covered for weight loss since its not FDA approved for weight loss.

Insurance 52

Insurance Customer Service Medication Guidelines Insurance Coverage 52

The FDA Law Blog

OCTOBER 12, 2023

Koblitz — For years, submitting a Suitability Petition has been like screaming into a void: You’d be lucky if FDA ever responds. This has been a big problem because FDA’s inattentiveness can delay entry of certain types of ANDAs for years—often resulting in the ANDA applicant’s abandonment of the Suitability Petition. Under 21 C.F.R.

FDA 59

FDA Dosage 59

The Checkup by Singlecare

MARCH 31, 2025

Ozempic is the brand name for semaglutide, which is a medication thats FDA approved to treat high blood sugar in people with Type 2 diabetes. For example, its not listed as a side effect in the FDAs 2025 prescribing information. You should seek medical advice from your healthcare provider about your specific situation.

Dosage 52

Dosage Labelling Hospitals FDA 52

The Checkup by Singlecare

OCTOBER 8, 2024

Xigduo XR is a brand-name prescription medication approved by the Food and Drug Administration (FDA) for managing Type 2 diabetes in adults and children 10 years and older. Without insurance, the cost of Xigduo XR varies by dosage, averaging about $390 per month, but there are ways to make it more affordable.

Insurance 52

Insurance Dosage Generic Medicine FDA 52

ISPE

FEBRUARY 15, 2023

Regulatory Activities Over recent years, several regulatory agencies have established initiatives to promote pharmaceutical manufacturing innovation: USA : FDA established the Emerging Technology Program in 2014 and has actively promoted the program.

FDA 95

FDA Dosage 95

Pharmacy Times

JUNE 17, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. The abstract was originally shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

Dosage 65

Dosage Compounding Pharmacies Immunization Chemotherapy 65

PharmTech

JUNE 23, 2025

Pharmacist weighing chemical | Image Credit: © Kzenon - stock.adobe.com Performing calculations for the formulation of pharmaceutical dosage forms and related preparations is a key activity in compounding. Active moiety calculations determine the drug amount needed to prepare the dosage form quantity. Pluta Nishant B.

Compounding 52

Compounding Dosage Labelling FDA 52

The Checkup by Singlecare

NOVEMBER 29, 2022

Namzaric is a prescription combination drug FDA approved to treat moderate to severe dementia due to Alzheimer’s disease. Unfortunately, there are no generic versions of extended-release memantine/donepezil, and there won’t be until 2025. Is Namzaric covered by insurance? | How much does Namzaric cost without insurance? |

Insurance 52

Insurance Insurance Coverage Dosage FDA 52

PharmTech

JUNE 6, 2025

Biosimilars continue to build as a sector of this market with an estimated 2025 value in the region of US$42 billion (1). Mordorintelligence.com (accessed May 5, 2025). 5 June 2025 Page: 22–28 Citation When referring to this article, please cite it as Easton, R. Pharmaceutical Technology 2025 49 (5). Specifications.

Dosage 52

Dosage Documentation Labelling FDA 52

Pharmacy Times

JUNE 13, 2025

In addition, the dosage [of 2000 IU per day] used in the research is far below the target dose for correcting vitamin D deficiency, which is usually 50,000 IU per week,” Carvalho-Pessoa said in a news release. Accessed June 13, 2025. June 12, 2025. Accessed June 13, 2025. Updated April 7, 2025. P = 0.04).

Chemotherapy 141

Chemotherapy Immunization Compounding Pharmacies Hospitals 141

ISPE

SEPTEMBER 8, 2023

USA The FDA established the Emerging Technology Program (ETP) in 2014 and has actively promoted the program 8. www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/emerging-technology-program 9 US Food and Drug Administration Center for Drug Evaluation and Research. 22 June 2023. 22 June 2023. EMA/321483/2020. 3 July 2020.

FDA 52

FDA Documentation Dosage Communication 52

Pharmacy Times

JUNE 23, 2025

Soefje, PharmD, MBA, BCOP, during the Hematology/Oncology Pharmacy Association (HOPA) 2025 Annual Conference in Portland, Oregon. The Orange Book is the reference, and it allows the FDA to declare something [to be] therapeutically equivalent.

FDA 65

FDA Compounding Pharmacies Dosage Hospitals 65

Pharmacy Times

JUNE 10, 2025

Meloxicam injection (Xifyrm; Azurity Pharmaceuticals, Inc) received FDA approval for use in adults for the management of moderate-to-severe pain, either alone or in combination with non-steroidal anti-inflammatory drug (NSAID) analgesics. June 10, 2025. Accessed June 10, 2025. Korean Journal of Anesthesiology. August 24, 2018.

FDA 73

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals 73

Pharmacy Times

JUNE 16, 2025

The biosimilar demonstrated comparable efficacy and safety to Stelara in a phase 3 clinical trial, supporting its FDA approval. Steqeyma provides a new dosage form and strength, enhancing treatment flexibility for young patients with chronic inflammatory conditions. In December 2024, the FDA approved the biosimilar in 45-mg/0.5

FDA 104

FDA Compounding Pharmacies Immunization Vaccines 104

OctariusRx

MAY 27, 2025

Our 2025 Medication Calculations quiz is now available. Food and Drug Administration (FDA) receives more than 100,000 reports associated with a suspected medication error. If youre already part of our team, you can expect to see the 2025 Medication Calculations Quiz during our upcoming facility visit. Take the quiz and find out!

Long-Term Care Facilities 57

Long-Term Care Facilities Labelling Medication Labelling Documentation 57

Pharmacy Times

JUNE 17, 2025

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Proactive strategies in oncology care enhance financial sustainability and improve patient outcomes.

Mail-Order Pharmacies 73

Mail-Order Pharmacies Compounding Pharmacies Medical Records Dosage 73

Pharmacy Times

JUNE 19, 2025

2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025. In October 2024, CAR T therapy axicabtagene ciloleucel (Yescarta; Kite Pharma) received FDA regenerative medicine advanced therapy designation as a first-line treatment for high-risk large B-cell lymphoma. Accessed January 17, 2025.

Compounding 65

Compounding Compounding Pharmacies FDA Immunization 65

IDStewardship

JUNE 19, 2025

Authored By: Aneeka Chavda, MRPharmS, MSc, MCMI, PgDipClinPharm Posted 19 June 2025 Mycobacterium tuberculosis (TB ) is one of the leading causes of death globally. tuberculosis 4 , more recent research implies that this dosage falls at the lower end of the dose-response curve 5. The WHO reports that in 2023, around 10.8

HIV Treatment and Prevention Agents 130

HIV Treatment and Prevention Agents Adverse Reactions Dosage Labelling 130

The Checkup by Singlecare

JUNE 24, 2025

There are also compounded versions of tirzepatide and semaglutide, but they are not approved by the Food and Drug Administration (FDA). In fact, the FDA has directed American compounding pharmacies to stop producing these products. But they have different drug classifications, indications, and dosages.

Insurance Coverage 52

Insurance Coverage Compounding Insurance Dosage 52

Pharmacy Times

JUNE 20, 2025

Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Accessed May 15, 2025. Carlstrom, PharmD, BCOP , Joseph A. Kalis, PharmD, BCOP Key Takeaways Oncology pharmacy's complexity outpaces the generalist model, necessitating specialization for effective patient care and operational efficiency.

Compounding 65

Compounding Compounding Pharmacies Patient Care Immunization 65

Pharmacy Times

JUNE 20, 2025

Selection of an appropriate OTC analgesic should take into consideration various patient factors, including the patient’s overall health status, current medical conditions, and medication profile, as well as patient preferences, which are often influenced by dosage form, required dosing intervals, and cost of OTC medication. December 2018.

Compounding Pharmacies 65

Compounding Pharmacies Hospitals Immunization Compounding 65

Pharmacy Times

JUNE 18, 2025

Results and conclusions will be presented at the 2025 Oncology Pharmacists Connect meeting, promoting innovation and collaboration. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Compounding Pharmacies 65

Compounding Pharmacies Dosage Immunization Compounding 65

The Checkup by Singlecare

MARCH 10, 2025

The medication is available in both brand-name and compounded forms, although the compounded forms are not FDA approved. Some insurance plans may cover Ozempic for managing Type 2 diabetes , which is an indication that is approved by the Food and Drug Administration (FDA) to treat. Does insurance cover Ozempic? affected by a shortage).

Compounding 52

Compounding Insurance Insurance Coverage FDA 52

Pharmacy Times

JUNE 25, 2025

Image credit: LASZLO | stock.adobe.com Gabrail et al presented data from a novel strategy involving continuous subcutaneous (SC) infusion of lenalidomide in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. Subscribe Now!

Immunization 50

Immunization Compounding Pharmacies Hospitals Compounding 50

The Checkup by Singlecare

JUNE 6, 2025

Mounjaro and Ozempic are both approved by the Food and Drug Administration (FDA) for the treatment of Type 2 diabetes. Ozempic has two additional FDA-approved uses as well. Ozempic and Mounjaro are both FDA-approved for blood sugar control in the treatment of Type 2 diabetes. Finally, Ozempic and Mounjaro have different dosages.

Dosage 52

Dosage FDA Labelling 52

The Checkup by Singlecare

FEBRUARY 10, 2025

Food and Drug Administration ( FDA ) in 2014 for Type 2 diabetes. Since then, its FDA -approved uses have expanded, now including kidney disease, heart failure , and Type 2 diabetes. As of January 2025, only the Prasco version of dapagliflozin is available in pharmacies.

Dosage 52

Dosage Labelling Hospitals FDA 52

PharmTech

JUNE 6, 2025

In a press release on June 4, 2025, the company described this as a standalone, fully servo-controlled ceramic vial filler system, designed as a cart-mounted module that provides convenience and ease of portability between lines. June 4, 2025. Pharmaceutical Technology 2025 , 49 (5). Press Release. Forcinio, H.

Dosage 52

Dosage Packaging Vaccines FDA 52

The Checkup by Singlecare

APRIL 15, 2025

From pharmacy to pharmacy, the cost can certainly vary, but the dosage does not impact the expense significantly. The lower dosage is recommended for reduced kidney function, so your healthcare provider should help you determine your appropriate dosage. Without insurance, Paxlovid s retail price amounts to $400 per day.

Insurance 52

Insurance Insurance Coverage Dosage Labelling 52

Pharmacy Times

JUNE 16, 2025

Both agents received FDA approval for the treatment of patients with RRMM who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The investigators assessed a total of 90 patients who received talquetamab at a dosage of 0.8 Updated May 23, 2025.

Compounding Pharmacies 50

Compounding Pharmacies Immunization Vaccines FDA 50

PharmTech

JUNE 12, 2025

Moving and shaking The deal, approved unanimously by the boards of both companies, is expected to close in 2025, pending customary regulatory clearances and a minimum 80% share acceptance rate from CureVac shareholders—although BioNTech retains the option to reduce this threshold to 75% (1). June 12, 2025. billion (1). billion (1).

Dosage 52

Dosage Vaccines Packaging Compounding 52

PharmTech

JUNE 10, 2025

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1). Grandviewresearch.com (accessed May 19, 2025). Next-Generation Biotherapeutics eBook 2025 April.

Dosage 52

Dosage Vaccines Compounding Immunization 52

The Checkup by Singlecare

MARCH 21, 2024

The drug and its fellow SGLT2 inhibitors, Farxiga (dapagliflozin), Invokana (canagliflozin), Steglatro (ertugliflozin), and Brenzavvy (bexagliflozin), are approved by the Food and Drug Administration (FDA) for treatment of Type 2 diabetes. Although there is no generic version of Jardiance available currently, there may be as early as 2025.

Insurance 98

Insurance Adverse Reactions FDA Dosage 98

PharmTech

JUNE 20, 2025

All of our BIO 2025 coverage can be found at this page. June 15, 2025. June 16, 2025. June 18, 2025. This included a presence at the Biotechnology Innovation Organization (BIO) International Convention in Boston, from June 16–19, and visits to other major US cities including Philadelphia and Washington, DC (1). “The

Dosage 59

Dosage Vaccines Packaging Compounding 59

Pharmaceutical Technology

SEPTEMBER 22, 2022

In 2021, the WHO and the United Nations announced a plan to reduce premature mortality related to noncommunicable diseases, including cardiovascular disease, by 25% leading up to 2025. In 2013, the FDA first approved Vazkepa solely for the reduction of triglyceride levels for hypertriglyceridemia. Amarin’s net product revenue was $577.9

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA Dosage 52

The Checkup by Singlecare

SEPTEMBER 10, 2024

It is approved by the Food and Drug Administration (FDA) to treat plaque psoriasis , psoriatic arthritis , Crohn’s disease , and ulcerative colitis. There have been several biosimilars approved, including Wezlana , Selarsdi, and Pyzchiva, but they are not expected to be available until early 2025. What is a biosimilar?

FDA 52

FDA Vaccines Specialty Pharmacies Pharmaceutical Companies 52